Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer

Published:2024-01-19 Issue:13 Volume:20 Page:851-862
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Betts Keith A¹^ORCID,Gao Sophie¹^ORCID,Ray Saurabh²^ORCID,Schoenfeld Adam J³

Affiliation:

1. Health Economics & Outcome Research, Analysis Group Inc., Los Angeles, CA90071, USA

2. Health Economics & Outcome Research, Bristol Myers Squibb, Lawrenceville, NJ08648, USA

3. Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, NY10065, USA

Funder

Bristol Myers Squibb

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-0612

Reference39 articles.

1. Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives

2. OPDIVO (nivolumab) Prescribing Information . Bristol-Myers Squibb Company NJ USA (2023). (Accessed 5April2023). https://packageinserts.bms.com/pi/pi_opdivo.pdf

3. KEYTRUDA (pembrolizumab) Prescribing Information . Merck Sharp & Dohme LLC NJ USA (2023). (Accessed 5April2023). www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

4. LIBTAYO (cemiplimab) Prescribing Information . Regeneron Pharmaceuticals NY USA (2023). (Accessed 30May2023). www.regeneron.com/downloads/libtayo_fpi.pdf

5. TECENTRIQ (atezolizumab) Prescribing Information . Genentech CA USA (2023). (Accessed 30May2023). www.gene.com/download/pdf/tecentriq_prescribing.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy-Induced Anemia in Adults Incidence and Treatment;Journal of Bursa Faculty of Medicine;2024-05-29